LifeMD (NASDAQ:LFMD) Price Target Cut to $3.00 by Analysts at Lake Street Capital

LifeMD (NASDAQ:LFMD) had its target price decreased by investment analysts at Lake Street Capital from $5.00 to $3.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital‘s price target suggests a potential upside of 36.67% from the stock’s previous close.

A number of other equities analysts have also recently commented on LFMD. KeyCorp set a $5.00 target price on LifeMD and gave the company an “overweight” rating in a report on Friday, August 7th. Zacks Research raised LifeMD from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. BTIG Research cut their price target on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d)” rating on shares of LifeMD in a research report on Monday, November 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of LifeMD in a research note on Thursday, September 17th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, LifeMD presently has an average rating of “Moderate Buy” and an average price target of $7.14.

LifeMD Trading Up 32.6%

LifeMD stock traded up $0.54 during trading on Friday, hitting $2.19. The company had a trading volume of 5,892,427 shares, compared to its average volume of 1,033,151. LifeMD has a 1-year low of $1.60 and a 1-year high of $5.38. The company’s 50 day simple moving average is $2.62 and its 200-day simple moving average is $3.58. The stock has a market cap of $105.80 million, a price-to-earnings ratio of -43.89 and a beta of 2.19.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%. The company had revenue of $44.63 million for the quarter, compared to analyst estimates of $48.84 million. As a group, analysts forecast that LifeMD will post -0.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LifeMD

A number of hedge funds have recently bought and sold shares of the stock. Walleye Capital LLC acquired a new position in shares of LifeMD during the 2nd quarter worth about $1,338,000. Russell Investments Group Ltd. grew its position in shares of LifeMD by 5,801.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company’s stock valued at $1,300,000 after buying an additional 309,436 shares during the last quarter. Penn Capital Management Company LLC acquired a new stake in LifeMD during the 2nd quarter worth $926,000. Bank of America Corp DE purchased a new stake in LifeMD in the second quarter valued at $1,078,000. Finally, BlackRock Inc. lifted its position in LifeMD by 8.0% in the second quarter. BlackRock Inc. now owns 3,034,535 shares of the company’s stock valued at $12,533,000 after acquiring an additional 225,510 shares during the last quarter. Institutional investors and hedge funds own 35.52% of the company’s stock.

Key Stories Impacting LifeMD

Here are a few of the latest stories about LFMD:

• Positive Sentiment: LifeMD reported a Q3 loss of $0.11 per share, narrower than the consensus loss of $0.14. Adjusted EBITDA loss was about $0.4 million, within guidance and improved by roughly $3.1 million from Q2, partly due to lower selling, marketing, and other non-clinical expenses. LifeMD Reports Third Quarter 2026 Results
• Neutral Sentiment: Mizuho lowered its price target from $7 to $6 but maintained an “outperform” rating, signaling continued optimism despite the reduced target. Mizuho stock recommendations
• Negative Sentiment: Q3 revenue of $44.6 million missed the $48.8 million analyst estimate. The company also forecast Q4 revenue of $46–$49 million, versus a $61.4 million consensus, and FY2026 revenue of $188–$191 million, versus a $207.6 million consensus. The outlook gaps may weigh on expectations for near-term growth. LifeMD reports Q3 loss, misses revenue estimates

LifeMD Company Profile

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.